New web series explores path from ophthalmic research to patient access
pharmafile | April 28, 2026 | News story | Research and Development | Opthalmology
A new YouTube web series has been launched to examine how ophthalmic innovations progress from early research through to approved treatments and real-world use.
Eye to Market, developed by Eyecelerator in collaboration with Unither Pharmaceuticals and Ora, Inc aims to bring together perspectives from across the development process, including clinical research, manufacturing and commercialisation. The series will feature short, expert-led episodes focused on the practical challenges of translating scientific advances into therapies for patients.
Topics covered will include clinical development, regulatory strategy, manufacturing scale-up and global access, as well as approaches to patient-centred innovation.
Gil Kliman, Programme Director for Eyecelerator, said the initiative was intended to make the development process more transparent.
“By opening the conversation across disciplines, we hope to help innovators and partners navigate complexity and ultimately deliver better outcomes for patients,” he said.
For patients, delays in translating promising research into accessible treatments remain a key issue in ophthalmology, where conditions can lead to progressive and sometimes irreversible vision loss.
Unither Pharmaceuticals, a contract development and manufacturing organisation involved in the project, brings expertise in sterile production and drug delivery systems, while clinical research organisation Ora contributes experience in trial design and regulatory development.
Speakers in the series emphasised the importance of coordination between scientific, clinical and commercial teams. Ora’s Chief Scientific Officers, George Ousler and Keith Lane, said successful development requires “insight, experience, and empathy” alongside technical capability.
Episodes will be published on the Eyecelerator YouTube channel and shared through partner platforms. The series is aimed at a broad audience, including clinicians, researchers and industry stakeholders, but also reflects wider efforts to improve how new treatments reach patients in a timely and effective way.
